Business Context and Reporting Period
Company: Anteris Technologies Global Corp. (AVR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Anteris is a development-stage medical technology company focused on the DurAVR® Transcatheter Heart Valve (THV) System, designed to treat aortic stenosis. The company is currently advancing the PARADIGM Trial, a global pivotal study intended to support Premarket Approval (PMA) in the U.S. and CE Mark approval in Europe. Revenue is currently derived primarily from the sale of regenerative tissue products to 4C Medical Technologies, Inc.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Amount (in thousands) |
|---|---|
| Net Sales | $1,503 |
| Cost of Products Sold | $(347) |
| Gross Profit | $1,156 |
| Research & Development Expense | $(40,826) |
| Selling, General & Administrative Expense | $(15,334) |
| Operating Loss | $(55,004) |
| Net Loss (Attributable to Stockholders) | $(52,118) |
| Cash, Cash Equivalents & Restricted Cash | $260,894 |
| Net Cash Used in Operating Activities | $(49,477) |
| Net Cash Provided by Financing Activities | $298,634 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 28% to $1.5 million (vs. $1.2 million in 2025), driven by higher tissue product sales to 4C, offset by the cessation of sales to LeMaitre following the expiration of their agreement in January 2025.
- Expense Increases:
- R&D: Increased 24% to $40.8 million due to upscaling manufacturing capabilities, PARADIGM Trial activities, and higher stock-based compensation.
- SG&A: Increased 43% to $15.3 million due to headcount growth, stock-based compensation, and IT/consulting expenditures.
- Liquidity Transformation: Cash balances surged from $12.6 million (Dec 31, 2025) to $260.9 million (June 30, 2026). This was primarily driven by a January 2026 underwritten public offering and a private placement with Medtronic, generating approximately $320 million in gross proceeds.
- Investment Income: Other non-operating income increased significantly (1,633% YoY) to $4.1 million, reflecting interest earned on the newly raised capital.
Outlook, Risks, and Management Commentary
- Clinical Progress: The PARADIGM Trial recruitment commenced in the U.S. in May 2026 following FDA IDE approval and Medicare reimbursement eligibility. Recruitment also expanded in France following ANSM clearance.
- Capital Strategy: The company established an At-The-Market (ATM) equity offering program in May 2026, allowing for the sale of up to $250 million in shares. Management believes current cash reserves are sufficient for at least the next 12 months.
- Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of June 30, 2026, due to previously identified material weaknesses in internal control over financial reporting (specifically regarding segregation of duties and documentation). Remediation is ongoing.
- Regulatory Risks: Success depends on the PARADIGM Trial results and subsequent FDA PMA approval. There is no guarantee of approval or commercial success.
- Consolidation Change: The company ceased funding v2vmedtech but continues to consolidate it due to board control rights, despite owning only ~30% of voting interests.
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the $260.9 million cash balance to confirm the 12-month liquidity assertion.
- Internal Control Remediation: Monitor progress on remediation of material weaknesses in financial reporting controls.
- PARADIGM Trial Enrollment: Track patient enrollment rates and data milestones to assess the timeline for FDA PMA submission.
- Revenue Concentration: Note that nearly all revenue ($1.48 million of $1.5 million) comes from a single customer (4C Medical Technologies), and the supply agreement expired in June 2026 (though purchase orders continue).
- Future Lease Obligations: Review the $23.2 million in future undiscounted payments for a new long-term lease in Brooklyn Park, MN, which has not yet commenced.